The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

October 7, 2016

Common Issues in Treating Patients with HR+/ HER2-Negative Metastatic Breast Cancer

Dr Hope Rugo discusses some of the choices and challenges she’s faced with in treating patients with HR+/ HER2-negative metastatic breast cancer with the goal of helping patients live as long as possible and with the best quality of life.

August 15, 2016

Knowing and Treating Obscure GI Tumors

Phillip Boudreaux, MD, talks about how gastrointestinal tumors can be masked and not diagnosed as the primary cause of why some patients are morbidly sick.